Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of T89 for prevention and treatment of acute mountain sickness during rapid ascent to high altitude
CTR20212354Phase 3Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Compound Danshen in acute mountain sickness (AMS), sponsored by Tasly Pharmaceutical Group Co., Ltd.. Started Sep 2021; status: completed.
02
Drugs
Compound Danshen
03
Conditions
acute mountain sickness (AMS)
Beyond the preview
Go deeper on CTR20212354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212354.